Replies to post #227731 on Biotech Values

[miljenko]

One day diagnostic will advance and NASH-treatment (and probably initial diagnosis) will be followed without biopsy, but that is not current case for ICPT. Pumpers are promoting ICPT as GILD acquisition target (160-250?). Current NRx# point 300-degree opposite.

[DewDiligence]

CC slides from ICPT’s ‘NASH Commercial Day’:

http://ir.interceptpharma.com/static-files/076ed33d-3f9a-4605-a5ca-ed39c1695beb